NCT05873309Completed
The Role of OXytocin in Acute Ischemic Stroke reconvAlesceNcE: The ROXANE Study
Source: ClinicalTrials.gov · Last updated 4 Mar 2025
Brief summary (registry, in English)
Evidence suggests that oxytocin has a neuroprotective role on a systemic and cellular level in the context of acute ischemic stroke (AIS). The investigators therefore hypothesize that high levels of circulating oxytocin measured within the first 72 hours after symptom onset are associated with lower mortality and favorable outcome in acute ischemic stroke.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 386 (actual)
- First submitted
- 15 May 2023
- Start date
- 26 Apr 2023
- Primary completion date
- 23 Sept 2024
- Lead sponsor
- University Hospital, Basel, Switzerland
- Diseases
- Stroke
- NCT number
- NCT05873309
What you commit to
- Study type: Observational
- Participants enrolled: 386
- From 26 Apr 2023 to the primary completion date, 23 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hemorrhagic stroke or patients discharged from the hospital with a diagnosis different from ischemic stroke (i.e., stroke mimics)
Other
- Patients below 18 years
- Missing informed consent
Who the study is looking for
- Rapid onset of a focal neurologic deficit, with signs or symptoms persisting beyond 24 hours and not associated with infection, trauma, or tumor of the brain, severe metabolic disorders, or chronic degenerative neurologic disease; or
- the development of an acute focal neurologic deficit persisting \>24 hours in conjunction with brain imaging consistent with acute ischemic stroke. The CT or MRI may either show a new infarct or no change from the study performed at entry, i.e., the diagnosis is clinical and does not require CT/MRI confirmation. Secondary hemorrhagic infarction is permissible.
- First blood sample at the stroke unit is taken within 24 hours from symptom onset.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Basel Coordinator of this site? Confirm its status | Basel | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.